Beam Therapeutics' BEAM-301 Eliminates Starch Supplementation in Two Patients in Early Trial
Bitget2026/10/27 11:09- Beam Therapeutics reported initial Phase 1/2 results for BEAM-301 in six patients with glycogen storage disease type Ia on Oct. 27, 2026.
- Two of three patients receiving 40 mg achieved 15 hours of controlled fasting, eliminating daily starch supplementation at their latest assessments.
- Median fasting tolerance at Day 36 rose from 2.5 to 15 hours with 40 mg, versus 2.9 to 4.3 hours with 20 mg.
- Four of six patients experienced serious treatment-related adverse events; no dose-limiting toxicities occurred.
- Enrollment in the 60 mg cohort is underway; the company plans FDA discussions on a potential approval pathway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tokyo inflation and a BoJ rate decision come next for a flat Yen
Starbucks (SBUX.US) Q4 U.S. business recovers beyond expectations, new fiscal year growth guidance slows to 4%
Starbucks reported Q4 revenue of $9.14 billion, falling short of expectations. Same-store sales in the U.S. rose by 7.7%. Adjusted EPS was $0.80, exceeding forecasts.
Report: ECB officials tend to favor a rate hike in December, with inflation outlook being the key variable
According to media reports, officials from the European Central Bank generally believe that, based on current data and the economic impact of the Middle East war, if the inflation situation does not improve, the European Central Bank will raise interest rates by 25 basis points in December. Currently, the market is pricing an 85% probability of a 25 basis point rate hike by the ECB in December. Analysts note that although the ECB has left room for another rate increase in December, the Governing Council is laying the groundwork to end the current tightening cycle.
Crypto prices
More
